Neurobiological Technologies Performance
| NTIIDelisted Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Neurobiological Technologies are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neurobiological Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong forward indicators, Neurobiological Technologies is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Total Cashflows From Investing Activities | 15.2 M |
Neurobiological |
Neurobiological Technologies Relative Risk vs. Return Landscape
If you would invest 0.01 in Neurobiological Technologies on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Neurobiological Technologies or generate 0.0% return on investment over 90 days. Neurobiological Technologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Neurobiological, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurobiological Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobiological Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurobiological Technologies, and traders can use it to determine the average amount a Neurobiological Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NTII |
Based on monthly moving average Neurobiological Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobiological Technologies by adding Neurobiological Technologies to a well-diversified portfolio.
Neurobiological Technologies Fundamentals Growth
Neurobiological Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobiological Technologies, and Neurobiological Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobiological Stock performance.
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| EBITDA | 19.54 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Total Asset | 2.58 M | ||||
| Current Liabilities | 73 K | ||||
About Neurobiological Technologies Performance
By evaluating Neurobiological Technologies' fundamental ratios, stakeholders can gain valuable insights into Neurobiological Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurobiological Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurobiological Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. The company was founded in 1987 and is based in Emeryville, California. Neurobiological Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Neurobiological Technologies performance evaluation
Checking the ongoing alerts about Neurobiological Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobiological Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurobiological Technologies is not yet fully synchronised with the market data | |
| Neurobiological Technologies has some characteristics of a very speculative penny stock | |
| Neurobiological Technologies has a very high chance of going through financial distress in the upcoming years |
- Analyzing Neurobiological Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobiological Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Neurobiological Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobiological Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobiological Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobiological Technologies' stock. These opinions can provide insight into Neurobiological Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |